Trial Profile
A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Efavirenz (Primary) ; Ritonavir (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Jun 2009 New trial record.